CURE OF MICE BEARING P388 LEUKEMIA BY VINCRISTINE IN COMBINATION WITH A CALCIUM-CHANNEL BLOCKER
- 1 January 1985
- journal article
- research article
- Vol. 69 (5) , 523-525
Abstract
Mice inoculated with P388 leukemia were treated initially with vincristine (VCR) at a dose of either 1.5 or 2.0 mg/kg. After 1 wk, VCR (0.1 mg/kg) was given daily for 10 treatments, but no mice were cured with this regimen. However, when the calcium channel blocker verapamil (75 mg/kg) was administered with VCR at 1.5 or 2.0 mg/kg, lifespans were prolonged and 1 of 10 or 6 of 1 mice were cured, respectively. As reported previousy, verapamil renders less sensitive or resistant tumor cells susceptible to VCR by inhibiting the VCR efflux mechanism, especially in resistant cells. Therefore, verapamil in combination with VCR apparently can result in total cell kill under the conditions used.This publication has 7 references indexed in Scilit:
- POTENTIATION OF VINCRISTINE AND ADRIAMYCIN EFFECTS IN HUMAN HEMATOPOIETIC TUMOR-CELL LINES BY CALCIUM-ANTAGONISTS AND CALMODULIN INHIBITORS1983
- PROMOTION BY VERAPAMIL OF VINCRISTINE RESPONSIVENESS IN TUMOR-CELL LINES INHERENTLY RESISTANT TO THE DRUG1983
- INCREASED ACCUMULATION OF VINCRISTINE AND ADRIAMYCIN IN DRUG-RESISTANT P388-TUMOR CELLS FOLLOWING INCUBATION WITH CALCIUM-ANTAGONISTS AND CALMODULIN INHIBITORS1982
- OVERCOMING OF VINCRISTINE RESISTANCE IN P388 LEUKEMIA INVIVO AND INVITRO THROUGH ENHANCED CYTO-TOXICITY OF VINCRISTINE AND VINBLASTINE BY VERAPAMIL1981
- DIFFERENCES IN DRUG SENSITIVITY AMONG TUMOR-CELLS FROM PARENTAL TUMORS, SELECTED VARIANTS, AND SPONTANEOUS METASTASES1981
- CELL-SURFACE ANTIGENS - PROGNOSTIC IMPLICATIONS IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA1980
- ACUTE LYMPHOBLASTIC LEUKÆMIA IN CHILDREN: CLASSIFICATION AND PROGNOSISThe Lancet, 1977